Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.45 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570158 | 0.90 | CNR2 (0.56) | CNR2CNR1MEN1HTTKMT2A | |
| SCHEMBL11907794 | 0.87 | CNR2 (0.43) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL2745363 | 0.86 | CNR2 (0.45) | CNR2CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11907355 | 0.86 | CNR2 (0.56) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL11906828 | 0.85 | CNR2 (0.41) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL11906690 | 0.82 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL11907258 | 0.82 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL11906095 | 0.81 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL2745365 | 0.81 | CNR2 (0.44) | CNR2CNR1MEN1HTTKMT2A | |
| SCHEMBL5570156 | 0.78 | CNR2 (0.56) | CNR2CNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | CNR2 1/4885CNR1 2/4885MEN1 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.